Arterial Disease Across Vascular Beds․ Lipoprotein(a) as a Causal Risk Factor
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on X:
”Lipoprotein(a) [Lp(a)] is not just about coronary disease.
Robust genetic and population data confirm Lp(a) as a causal risk factor across multiple vascular beds.
- Peripheral Arterial Disease (PAD): Rising Lp(a) levels show a clear, stepwise association with PAD risk—up to ~3-fold higher risk at extreme concentrations.
- Major Adverse Limb Events (MALE): In patients with PAD, high Lp(a) markedly increases the risk of amputations and repeat revascularizations.
- Abdominal Aortic Aneurysm (AAA): Elevated Lp(a) is consistently associated with higher AAA risk, supported by Mendelian randomization.
- Inflammation matters—but doesn’t negate Lp(a) risk: Lp(a)-associated cardiovascular risk persists independently of hsCRP levels, in both primary and secondary prevention.
Clinical takeaway: Lp(a) identifies residual vascular risk beyond LDL-C and traditional factors—supporting routine measurement and future targeted therapy.
Phase 3 Lp(a)-lowering outcome trials may redefine prevention across coronary and non-coronary vascular disease.
Open Access here.
Article:Lipoprotein(a) in cardiovascular disease with focus on peripheral arterial disease, major adverse limb events, abdominal aortic aneurysms and interaction with low-grade inflammation
Authors: Peter E. Thomas, Signe Vedel-Krogh, Pia R. Kamstrup, Børge G. Nordestgaard
Stay updated on all scientific advances with Hemostasis Today.
-
May 30, 2026, 10:27Sartaj Alam: CBC Analyzer – The Backbone of Modern Hematology Diagnostics
-
May 30, 2026, 10:17Factor X Deficiency – From Mild Bruising to Life Threatening Hemorrhage – ICHCC
-
May 30, 2026, 10:06Johann Morelle: Complement Inhibitors Are Reshaping Modern Nephrology
-
May 30, 2026, 09:49Flora Peyvandi: Exploring a Multidisciplinary Care Model for Hemophilia and Rare Diseases
-
May 30, 2026, 08:59Li-Chia Chen: Advancing Patient Care Through Pharmacist Innovation at KUTRRH
-
May 30, 2026, 08:58Ben Creagh-Brown: How Should HI-PEITHO Influence the Management of Intermediate-Risk Pulmonary Embolism?
-
May 30, 2026, 08:56Reidiel Suárez Borges: Understanding the INR in Anticoagulation Management
-
May 29, 2026, 17:23Rita Schwab: Current Clinical Management of Trauma without the Use of Allogenic Blood Products
-
May 29, 2026, 17:22Brian Schiro: Excited to Provide Guideline Based Care at the Aortic Center